Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.43 |
| ▸ | FABP7 | O15540 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | FBP1 | P09467 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7268207 | 0.89 | CA1 (0.50) | CA1CA2KMT2AHTR2AFABP5 | |
| SCHEMBL29221536 | 0.86 | CA1 (0.47) | CA1CA2KMT2AHTR2AFABP5 | |
| SCHEMBL7269639 | 0.85 | CA1 (0.58) | CA1CA2KMT2AHTR2AFABP5 | |
| SCHEMBL29221537 | 0.83 | CA1 (0.45) | CA1CA2KMT2AHTR2AFABP5 | |
| SCHEMBL18736421 | 0.83 | CA1 (0.45) | CA1CA2KMT2AHTR2AFABP5 | |
| SCHEMBL7268282 | 0.81 | CA1 (0.50) | CA1CA2KMT2AHTR2AFABP5 | |
| SCHEMBL30865065 | 0.81 | CA1 (0.50) | CA1CA2KMT2AHTR2AFABP5 | |
| SCHEMBL29629442 | 0.78 | KMT2A (0.49) | CA1CA2KMT2AHTR2AFABP5 | |
| SCHEMBL17143722 | 0.77 | KMT2A (0.59) | KMT2AFABP5FABP7EPHX2PIN1 | |
| SCHEMBL30987806 | 0.77 | KMT2A (0.59) | KMT2AFABP5FABP7EPHX2PIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149064-B2 | Vasoactive polypeptides for smooth muscle relaxation | VANDERBILT UNIVERSITY (US) | 2021-10-19 | — | — | US | claimed |
| EP-3509613-A1 | VASOACTIVE POLYPEPTIDES FOR SMOOTH MUSCLE RELAXATION | Vanderbilt University (US) | 2019-07-17 | — | — | EP | claimed |
| WO-2018049071-A1 | VASOACTIVE POLYPEPTIDES FOR SMOOTH MUSCLE RELAXATION | VANDERBILT UNIVERSITY (US) | 2018-03-15 | — | — | WO | claimed |
| EP-3125943-B1 | PHOSPHATE BASED LINKERS FOR INTRACELLULAR DELIVERY OF DRUG CONJUGATES | MERCK SHARP & DOHME LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20230099074-A1 | ANTIBODY DRUG CONJUGATE FOR ANTI-INFLAMMATORY APPLICATIONS | MERCK SHARP & DOHME LLC (US) | 2023-03-30 | — | — | US | disclosed |
| US-20230099074-A1 | ANTIBODY DRUG CONJUGATE FOR ANTI-INFLAMMATORY APPLICATIONS | MERCK SHARP & DOHME LLC (US) | 2023-03-30 | — | — | US | disclosed |
| US-11510993-B2 | Antibody drug conjugate for anti-inflammatory applications | MERCK SHARP & DOHME LLC (US) | 2022-11-29 | — | — | US | disclosed |
| US-11149064-B2 | Vasoactive polypeptides for smooth muscle relaxation | VANDERBILT UNIVERSITY (US) | 2021-10-19 | — | — | US | disclosed |
| US-20200164085-A1 | ANTIBODY DRUG CONJUGATE FOR ANTI-INFLAMMATORY APPLICATIONS | MERCK SHARP & DOHME LLC | 2020-05-28 | — | — | US | disclosed |
| US-20200164085-A1 | ANTIBODY DRUG CONJUGATE FOR ANTI-INFLAMMATORY APPLICATIONS | MERCK SHARP & DOHME LLC | 2020-05-28 | — | — | US | disclosed |
| US-10550190-B2 | Phosphate based linkers for intracellular delivery of drug conjugates | MERCK SHARP & DOHME CORP. (US) | 2020-02-04 | — | — | US | disclosed |
| US-7135453-B2 | Reagents and methods for smooth muscle therapies | ARIZONA BOARD OF REGENTS (US) | 2006-11-14 | — | — | US | disclosed |
| EP-1594526-B1 | USE OF HSP20 FOR PROMOTING WOUND HEALING AND/OR REDUCING SCAR FORMATION | UNIV ARIZONA (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20060035814-A1 | Reagents and methods for smooth muscle therapies | ARIZONA BOARD OF REGENTS | 2006-02-16 | — | — | US | disclosed |
| EP-1594526-A1 | METHODS FOR PROMOTING WOUND HEALING AND/OR REDUCING SCAR FORMATION | The Arizona Board of Regents (US) | 2005-11-16 | — | — | EP | disclosed |
| EP-1523323-A2 | REAGENTS AND METHODS FOR SMOOTH MUSCLE THERAPIES | Arizona Board of Regents (US) | 2005-04-20 | — | — | EP | disclosed |
| WO-2004075914-A1 | METHODS FOR PROMOTING WOUND HEALING AND/OR REDUCING SCAR FORMATION | ARIZONA BOARD OF REGENTS (US) | 2004-09-10 | — | — | WO | disclosed |
| WO-2004017912-A2 | METHODS FOR INCREASING THE RATE OF HEART MUSCLE CONTRACTION | ARIZONA BOARD OF REGENTS, A BODY CORPORATE ACTING ON BEHALF OF ARIZONA STATE UNIVERSITY, OFFICE OF TECHNOLOGY COLLABORATION AND LICENSING (US) | 2004-03-04 | — | — | WO | disclosed |
| US-20030060399-A1 | Reagents and methods for smooth muscle therapies | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-03-27 | — | — | US | disclosed |
| WO-2003018758-A2 | REAGENTS AND METHODS FOR SMOOTH MUSCLE THERAPIES | ARIZONA BOARD OF REGENTS (US) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200164085-A1 | ANTIBODY DRUG CONJUGATE FOR ANTI-INFLAMMATORY APPLICATIONS | CD44, FCGR2A, TNF | CA1 1243/4885CA2 300/4885KMT2A 4262/4885 |
| US-11510993-B2 | Antibody drug conjugate for anti-inflammatory applications | CD44, FCGR2A, TNF | CA1 1243/4885CA2 300/4885KMT2A 4262/4885 |
| US-20230099074-A1 | ANTIBODY DRUG CONJUGATE FOR ANTI-INFLAMMATORY APPLICATIONS | CD44, FCGR2A, TNF | CA1 1243/4885CA2 300/4885KMT2A 4262/4885 |
| US-10550190-B2 | Phosphate based linkers for intracellular delivery of drug conjugates | CD47, PLPBP, CHERP | CA1 2716/4885CA2 1112/4885KMT2A 3139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.